BRPI0605484A2 - toxina ph(alfa)1b, cdna do gene da toxina ph(alfa)1b, composições farmacêuticas contendo a toxina ph(alfa)1b, processo para sua obtenção, processo para obtenção do cdna, e produto - Google Patents

toxina ph(alfa)1b, cdna do gene da toxina ph(alfa)1b, composições farmacêuticas contendo a toxina ph(alfa)1b, processo para sua obtenção, processo para obtenção do cdna, e produto

Info

Publication number
BRPI0605484A2
BRPI0605484A2 BRPI0605484-6A BRPI0605484A BRPI0605484A2 BR PI0605484 A2 BRPI0605484 A2 BR PI0605484A2 BR PI0605484 A BRPI0605484 A BR PI0605484A BR PI0605484 A2 BRPI0605484 A2 BR PI0605484A2
Authority
BR
Brazil
Prior art keywords
toxin
obtaining
alpha
cdna
pharmaceutical compositions
Prior art date
Application number
BRPI0605484-6A
Other languages
English (en)
Inventor
Gomes Marcus Vinicius
Marco Antonio Maximo Prado
Vania Fatima Prado
Original Assignee
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais filed Critical Univ Minas Gerais
Priority to BRPI0605484A priority Critical patent/BRPI0605484A8/pt
Priority to CA002669975A priority patent/CA2669975A1/en
Priority to US12/515,619 priority patent/US8383162B2/en
Priority to PCT/BR2007/000318 priority patent/WO2008061329A2/en
Priority to EP07815759A priority patent/EP2086558A2/en
Publication of BRPI0605484A2 publication Critical patent/BRPI0605484A2/pt
Publication of BRPI0605484A8 publication Critical patent/BRPI0605484A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Insects & Arthropods (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

TOXINA Ph<244>1B, cDNA DO GENE DA TOXINA Ph<244>1B, COMPOSIçõES FARMACEUTICAS CONTENDO A TOXINA Ph<244>1B, PROCESSO PARA SUA OBTENçãO, PROCESSO PARA OBTENçãO DO cDNA, E PRODUTO. A presente invenção se refere ao isolamento de toxinas do veneno da aranha Phoneutria nigriventer e o uso destas toxinas como inibidores da função de canais jónicos, mais especificamente, como bloqueadores de canais de cálcio no sistema nervoso central e neuromuscular de organismos, incluindo humanos. A invenção compreende, ainda, o isolamento, descrição da proteína e cadeia de aminoácidos presentes na toxina, seu uso em composições farmacêuticas, utilização no tratamento de problemas relacionados às desordens neurológicas, desordens neurodegenerativas, processos dolorosos, e principalmente como bloqueadora de canais de cálcio tipo N, bem como obtenção do cDNA do gene da toxina Ph<244>1B.
BRPI0605484A 2006-11-21 2006-11-21 Toxina ph(alfa)1b, cdna do gene da toxina ph(alfa)1b, composições farmacêuticas contendo a toxina ph(alfa)1b, processo para sua obtenção, processo para obtenção do cdna, e produto BRPI0605484A8 (pt)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0605484A BRPI0605484A8 (pt) 2006-11-21 2006-11-21 Toxina ph(alfa)1b, cdna do gene da toxina ph(alfa)1b, composições farmacêuticas contendo a toxina ph(alfa)1b, processo para sua obtenção, processo para obtenção do cdna, e produto
CA002669975A CA2669975A1 (en) 2006-11-21 2007-11-21 Ph.alpha.1b toxin, cdna of ph.alpha.1b toxin gene, pharmaceutical compositions containing ph.alpha.1b toxin, processes for their obtention and product
US12/515,619 US8383162B2 (en) 2006-11-21 2007-11-21 PHα1B toxin, CDNA of PHα1B toxin gene, pharmaceutical composition containing PHα1B toxin, process for their production and product
PCT/BR2007/000318 WO2008061329A2 (en) 2006-11-21 2007-11-21 PHα1B TOXIN, CDNA OF PHα1 B TOXIN GENE, PHARMACEUTICAL COMPOSITIONS CONTAINING PHα1B TOXIN, PROCESSES FOR THEIR OBTENTION AND PRODUCT
EP07815759A EP2086558A2 (en) 2006-11-21 2007-11-21 Ph 1b toxin, cdna of ph 1 b toxin gene, pharmaceutical compositions containing ph 1b toxin, processes for their obtention and product

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0605484A BRPI0605484A8 (pt) 2006-11-21 2006-11-21 Toxina ph(alfa)1b, cdna do gene da toxina ph(alfa)1b, composições farmacêuticas contendo a toxina ph(alfa)1b, processo para sua obtenção, processo para obtenção do cdna, e produto

Publications (2)

Publication Number Publication Date
BRPI0605484A2 true BRPI0605484A2 (pt) 2009-12-29
BRPI0605484A8 BRPI0605484A8 (pt) 2017-03-07

Family

ID=39430081

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0605484A BRPI0605484A8 (pt) 2006-11-21 2006-11-21 Toxina ph(alfa)1b, cdna do gene da toxina ph(alfa)1b, composições farmacêuticas contendo a toxina ph(alfa)1b, processo para sua obtenção, processo para obtenção do cdna, e produto

Country Status (5)

Country Link
US (1) US8383162B2 (pt)
EP (1) EP2086558A2 (pt)
BR (1) BRPI0605484A8 (pt)
CA (1) CA2669975A1 (pt)
WO (1) WO2008061329A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068388A3 (pt) * 2015-09-18 2017-08-03 Universidade Federal De Minas Gerais - Ufmg Uso do peptideo sintetico pntx-19 para tratamento de dor

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016295423B2 (en) * 2015-07-17 2020-09-03 Monash University Neuroprotective agents derived from spider venom peptides
KR101613302B1 (ko) * 2015-12-30 2016-04-18 (주)넥스젠바이오텍 Sv82 폴리펩타이드 및 이를 유효성분으로 함유하는 피부 주름 개선 및 탄력 유지용 화장료 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689450A4 (en) 1993-03-18 1997-05-21 Nps Pharma Inc THE CALCIUM CHANNELS BLOCKING CONNECTIONS AND THEIR USE
ATE466873T1 (de) 2005-10-18 2010-05-15 Seoul Nat Univ Ind Foundation Verfahren zur herstellung eines rekombinanten peptids aus spinnengift, und das peptid enthaltende analgetische zusammensetzung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068388A3 (pt) * 2015-09-18 2017-08-03 Universidade Federal De Minas Gerais - Ufmg Uso do peptideo sintetico pntx-19 para tratamento de dor

Also Published As

Publication number Publication date
US8383162B2 (en) 2013-02-26
EP2086558A2 (en) 2009-08-12
US20100168009A1 (en) 2010-07-01
WO2008061329A3 (en) 2008-07-24
CA2669975A1 (en) 2008-05-29
WO2008061329A2 (en) 2008-05-29
BRPI0605484A8 (pt) 2017-03-07

Similar Documents

Publication Publication Date Title
BR0314721A (pt) Compostos tricìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo-os
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
BRPI0509069A (pt) compostos de imidazol para o tratamento de distúrbios neurodegenerativos
BRPI0512335A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
BRPI0715746B8 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
BRPI0808764B8 (pt) compostos espiro-substituídos como inibidores de angiogênese seu processo de produção e composição farmacêutica
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
BRPI0609719B8 (pt) derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
SE0301010D0 (sv) Novel compounds
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
BR0317358A (pt) Composto de pirrolopiridazina, processo para sua preparação, composição farmacêutica contendo o mesmo, método de prevenção ou tratamento de doenças contendo o mesmo e seu uso
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
SE0301009D0 (sv) Novel compounds
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
UY29161A1 (es) Nuevos heterociclos
BRPI0615691A8 (pt) Método para a preparação de 6-((3s,4r)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il) hexanoato de (r)-quinuclidin-3-ila ou sal do mesmo
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
BRPI0518907A2 (pt) compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodo para o tratamento e/ou prevenÇço de enfermidades que estço associadas com a modulaÇço de receptores de h3 e sua utilizaÇço
BRPI0413709A (pt) compostos para o tratamento de distúrbios neurodegenerativos

Legal Events

Date Code Title Description
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 014070009218/ MG DE 21/12/2007 EM VIRTUDE DO DISPOSTO NO ART. 219, 2O DA LPI.

B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B12C Appeal against dismissal [chapter 12.3 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG (BR/MG

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 14140001602/MG DE 05/09/2014, E NECESSARIO APRESENTAR DOCUMENTO DE CESSAO COM AS ASSINATURAS COM FIRMAS RECONHECIDAS DO CEDENTE E DOS CESSIONARIOS, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG (BR/MG

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL